FDA Should Seek Outside Input On Breast Implant Consent Issues - Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA should confer with the American Society of Plastic Surgeons and other appropriate professional societies regarding the types of information that should be provided to breast implant recipients regarding differences in surgical procedures and post-operative care, members of the agency's General and Plastic Surgery Devices Panel recommended March 3 in Gaithersburg, Maryland.
You may also be interested in...
Mentor, Inamed Saline Breast Implants Deemed Approvable By FDA Panel
Saline breast implants manufactured by Mentor Corp. and Inamed Corp. should remain on the U.S. market provided the device manufacturers beef up labeling and physician training to help insure that patients are fully informed of any possible adverse outcomes, FDA's General and Plastic Surgery Devices Advisory Panel recommended at a March 1 meeting in Gaithersburg, Maryland.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.